Description: SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ Cell Therapy Platform, which uses membrane disruption to deliver material into cells. The company was founded in March 2013 and is headquartered in Watertown, MA.
Home Page: www.sqzbiotech.com
SQZ Technical Analysis
200 Arsenal Yards Boulevard
Watertown,
MA
02472
United States
Phone:
617 758 8672
Officers
| Name | Title |
|---|---|
| Dr. Howard Bernstein M.D., Ph.D. | Interim CEO & Director |
| Mr. Lawrence J. Knopf | Gen. Counsel |
| Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD | Co-Founder & Member of Scientific Advisory Board |
| Mr. Micah Zajic | Chief Financial Officer |
| Mr. Richard V. Capasso CPA | Chief Accounting Officer |
| Mr. David First | Chief People Officer |
| Dr. Marshelle Smith Warren M.D. | Chief Medical Officer |
| Ipsita Roymoulik Ph.D. | Sr. VP of CMC & QUALITY |
Exchange: NYSE
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4982 |
| Price-to-Sales TTM: | 1.2437 |
| IPO Date: | 2020-10-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 113 |